Quick Answer: GLP-1 receptor agonists produce modest cholesterol reductions (LDL-C by 2-10%, triglycerides by 10-20%) but should complement, not replace, statin therapy for lipid management
The peptide mimetic DPP-4 inhibitors including vildagliptin, saxagliptin and teneligliptin, were identified by peptide-based substrate substitution experiments, while the non-peptide mimetic group such as sitagliptin, alogliptin and linagliptin, were derived from the inhibitor and initially found in random screening
What is the difference between tirzepatide v ersus semaglutide for weight loss
Patients taking statins who develop new muscle symptoms while on GLP-1 therapy should contact their prescriber promptly, as this combination may increase the risk of muscle-related adverse effects in some individuals
Clinical trials suggest tirzepatide may provide significant reductions in both HbA1c (a measure of long-term blood sugar control) and body weight
Serving PGA West, La Quinta Cove, La Quinta Country Club, Griffin Ranch, Trilogy at La Quinta, The Madison Club, and Old Town La Quinta
